Diagnostics (Jun 2022)

Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review

  • Jasjit S. Suri,
  • Mahesh A. Maindarkar,
  • Sudip Paul,
  • Puneet Ahluwalia,
  • Mrinalini Bhagawati,
  • Luca Saba,
  • Gavino Faa,
  • Sanjay Saxena,
  • Inder M. Singh,
  • Paramjit S. Chadha,
  • Monika Turk,
  • Amer Johri,
  • Narendra N. Khanna,
  • Klaudija Viskovic,
  • Sofia Mavrogeni,
  • John R. Laird,
  • Martin Miner,
  • David W. Sobel,
  • Antonella Balestrieri,
  • Petros P. Sfikakis,
  • George Tsoulfas,
  • Athanase D. Protogerou,
  • Durga Prasanna Misra,
  • Vikas Agarwal,
  • George D. Kitas,
  • Raghu Kolluri,
  • Jagjit S. Teji,
  • Mustafa Al-Maini,
  • Surinder K. Dhanjil,
  • Meyypan Sockalingam,
  • Ajit Saxena,
  • Aditya Sharma,
  • Vijay Rathore,
  • Mostafa Fatemi,
  • Azra Alizad,
  • Padukode R. Krishnan,
  • Tomaz Omerzu,
  • Subbaram Naidu,
  • Andrew Nicolaides,
  • Kosmas I. Paraskevas,
  • Mannudeep Kalra,
  • Zoltán Ruzsa,
  • Mostafa M. Fouda

DOI
https://doi.org/10.3390/diagnostics12071543
Journal volume & issue
Vol. 12, no. 7
p. 1543

Abstract

Read online

Background and Motivation: Parkinson’s disease (PD) is one of the most serious, non-curable, and expensive to treat. Recently, machine learning (ML) has shown to be able to predict cardiovascular/stroke risk in PD patients. The presence of COVID-19 causes the ML systems to become severely non-linear and poses challenges in cardiovascular/stroke risk stratification. Further, due to comorbidity, sample size constraints, and poor scientific and clinical validation techniques, there have been no well-explained ML paradigms. Deep neural networks are powerful learning machines that generalize non-linear conditions. This study presents a novel investigation of deep learning (DL) solutions for CVD/stroke risk prediction in PD patients affected by the COVID-19 framework. Method: The PRISMA search strategy was used for the selection of 292 studies closely associated with the effect of PD on CVD risk in the COVID-19 framework. We study the hypothesis that PD in the presence of COVID-19 can cause more harm to the heart and brain than in non-COVID-19 conditions. COVID-19 lung damage severity can be used as a covariate during DL training model designs. We, therefore, propose a DL model for the estimation of, (i) COVID-19 lesions in computed tomography (CT) scans and (ii) combining the covariates of PD, COVID-19 lesions, office and laboratory arterial atherosclerotic image-based biomarkers, and medicine usage for the PD patients for the design of DL point-based models for CVD/stroke risk stratification. Results: We validated the feasibility of CVD/stroke risk stratification in PD patients in the presence of a COVID-19 environment and this was also verified. DL architectures like long short-term memory (LSTM), and recurrent neural network (RNN) were studied for CVD/stroke risk stratification showing powerful designs. Lastly, we examined the artificial intelligence bias and provided recommendations for early detection of CVD/stroke in PD patients in the presence of COVID-19. Conclusion: The DL is a very powerful tool for predicting CVD/stroke risk in PD patients affected by COVID-19.

Keywords